Cantor Fitzgerald maintains Neutral rating on Pfizer stock at $24 price target

Investing.com - Cantor Fitzgerald maintained its Neutral rating on Pfizer (NYSE:PFE) with a price target of $24.00, according to a research note released Wednesday. According to InvestingPro data, the stock appears undervalued at its current price of $25.04, with analysts’ targets ranging from $24 to $38.

The research firm acknowledged Pfizer’s ability to deliver earnings per share (EPS) and outperform growth-challenged peers like Merck and Bristol Myers Squibb. Trading at a P/E ratio of 13.01 and offering a substantial 6.98% dividend yield, Pfizer has maintained dividend payments for 55 consecutive years. Cantor Fitzgerald specifically noted Pfizer’s execution amid challenges facing Bristol Myers Squibb with ADEPT-2 and Merck’s fiscal year 2025 guidance that remains uncertain.

Despite the positive execution, Cantor Fitzgerald believes there remains a ceiling on how much Pfizer shares can appreciate due to long-term growth challenges facing the pharmaceutical company.

The firm sees potential upside to EPS estimates for 2025 and 2026, suggesting Pfizer may exceed current market expectations for those years.

Pfizer, like other major pharmaceutical companies, continues to navigate a complex industry landscape while working to deliver shareholder value through earnings performance.

In other recent news, Pfizer Inc. reported its second-quarter earnings for 2025, which exceeded analyst expectations. The company announced an earnings per share of $0.78, surpassing the forecasted $0.57, and reported revenue of $14.7 billion, beating the anticipated $13.47 billion. Additionally, the U.S. Food and Drug Administration has accepted the New Drug Application for vepdegestrant, a treatment for ESR1-mutated breast cancer, developed in collaboration with Arvinas, Inc. The FDA has set a Prescription Drug User Fee Act action date for June 5, 2026. In another development, Morgan Stanley has raised its price target for Pfizer stock to $33.00 from $32.00, maintaining an Equalweight rating. This adjustment follows Pfizer’s recent earnings report and insights into the biopharmaceutical policy landscape. These recent developments reflect ongoing progress and adjustments within Pfizer’s operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.